

## Technology Appraisal Committee Meeting (Committee D)

**Minutes:** Confirmed

**Date and Time:** Thursday 24 November 2016, 10.00am – 4.45pm

**Venue:** National Institute for Health and Care Excellence  
Level 1A, City Tower  
Piccadilly Plaza  
Manchester  
M1 4BT

<b>Present:</b>	1. Professor Gary McVeigh, Chair	Present for all notes
	2. Dr Lindsay Smith, Vice Chair	Present for all notes
	3. Dr Aomesh Bhatt	Present for all notes
	4. Dr Andrew Black	Present for all notes
	5. Dr Ian Campbell	Present for notes 1 to 39
	6. Dr Ian Davidson	Present for all notes
	7. Professor Simon Dixon	Present for all notes
	8. Susan Dutton	Present for all notes
	9. Gillian Ells	Present for all notes
	10. Professor Paula Ghaneh	Present for all notes
	11. Dr Susan Griffin	Present for all notes
	12. Professor John Henderson	Present for all notes
	13. Sumithra Maheswaran	Present for all notes
	14. Professor David Meads	Present for all notes
	15. Dr Malcolm Oswald	Present for all notes
	16. Professor Oluwafemi Oyeboode	Present for all notes
	17. Dr Paula Parvulescu	Present for all notes
	18. Dr Mohit Sharma	Present for all notes

### In attendance:

Dr Nigel Armstrong	Assessment Group representative, Kleijnen Systematic Reviews	Present for notes 5 to 16
Orsolya Balogh	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 29 to 40
Laura Bojke	Evidence Review Group representative, Centre for Reviews and Dissemination and Centre for Health Economics – York	Present for notes 17 to 28
Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for notes 1-16 and 29-40

Mark Corbett	Evidence Review Group representative, Centre for Reviews and Dissemination and Centre for Health Economics – York	Present for notes 17 to 28
Chris Curtis	Patient Expert, nominated by the Swallows Head and Neck Cancer Support Charity	Present for notes 5 to 16
Dr Sally Doss	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 29 to 40
Henk Giele	Consultant Surgeon, Department of Plastic Reconstructive and Hand Surgery, Clinical Expert, nominated by the British Dupuytren's Society	Present for notes 29 to 37
Professor Kevin Harrington	Professor of Biological Cancer Therapies, Clinical Expert, nominated by Bristol-Myers Squibb	Present for notes 5 to 16
Sana Khan	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 16
Dr Anthony Kong	Clinical Senior Lecturer and Honorary NHS Consultant in Clinical Oncology, Clinical Expert, nominated by the Royal College of Physicians	Present for notes 5 to 16
Helen Knight	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Fay McCracken	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 17 to 28

Kate Moore	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Bram Ramaekers	Assessment Group representative, Kleijnen Systematic Reviews	Present for notes 5 to 16
Anna Schurer	Patient Expert, nominated by the British Dupuytren's Society	Present for notes 29 to 37
Alex Sexton	Administrator, National Institute for Health and Care Excellence	Present for all notes
Dr Paul Tappenden	Senior Research Fellow, Decision Support Unit	Present for notes 29 to 40
Aminata Thiam	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 17 to 28
Nwamaka Umeweni	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 1 to 16

**Non-public observers:**

John Borrill	Technical Advisor, Scientific Advice, National Institute for Health and Care Excellence	Present for all notes
Carl Boswell	Programme Manager, PASLU, National Institute for Health and Care Excellence	Present for notes 17 to 28
Luan Linden-Phillips	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 16
Hayley Sharp	Senior Medical Editor, National Institute for Health and Care Excellence	Present for all notes
Lydia Shears	Public Involvement Advisor, National Institute for Health and	Present for notes 1 to 16

## **Welcome**

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy, certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs, and collagenase clostridium histolyticum for treating Dupuytren's contracture.
2. The Chair thanked Dr Ian Campbell and Professor John Henderson, who were attending their last meeting, for all their work as members of the Appraisal Committee.
3. Apologies were received from Professor David Bowen, Dr Matthew Bradley, and Tracey Cole.

## **Any other Business**

4. None

## **Appraisal of nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy**

### **Part 1 – Open session**

5. The Chair welcomed the invited experts, Dr Nigel Armstrong, Chris Curtis, Professor Kevin Harrington, Dr Anthony Kong, and Bram Ramaekers, to the meeting and they introduced themselves to the committee.
6. The Chair welcomed company representatives from Bristol-Myers Squibb to the meeting.
7. The Chair asked all Committee members to declare any relevant interests:
  - 7.1. Dr Aomesh Bhatt, Dr Andrew Black, Dr Ian Campbell, Dr Ian Davidson, Susan Dutton, Gillian Ells, Professor Paula Ghaneh, Dr Susan Griffin, Sumithra Maheswaran, Professor Gary McVeigh, Professor David Meads, Malcolm Oswald, Professor Oluwafemi Oyeboode, Dr Paula Parvulescu, Dr Mohit Sharma and Dr Lindsay Smith all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be

considered as part of the appraisal of nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy.

- 7.2. Professor Simon Dixon declared a non-personal non-specific financial interest as he is Director of a Health Economics Unit that has undertaken research for a comparator company on unrelated topics. He was not directly involved in the work and the University of Sheffield received payment for the work.
  - 7.2.1 It was agreed that this declaration would not prevent Professor Simon Dixon from participating in this section of the meeting.
- 7.3. Professor John Henderson declared a non-personal non-specific financial interest as his institution has undertaken research for a comparator company on unrelated topics. He did not receive personal remuneration for this work.
  - 7.3.1 It was agreed that this declaration would not prevent Professor John Henderson from participating in this section of the meeting.
8. The Chair asked all NICE Staff to declare any relevant interests.
  - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy.
9. The Chair asked all other invited guests to declare their relevant interests.
  - 9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy.
10. The Chair noted that since the outcome of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency had not yet been received, the discussion of this appraisal would be held as Part 2 as closed discussion, having regard to 'the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest' (Section 1(2) Public Bodies (Admission to Meetings) Act 1960).

## **Part 2 – Closed session**

11. The Chair introduced the lead team, Professor Simon Dixon, Gillian Ells and Malcolm Oswald, who gave presentations on the clinical effectiveness and cost effectiveness of nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy.
12. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

13. The Committee continued to discuss the clinical and cost effectiveness of nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy
14. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.
15. The Committee continued to discuss the clinical and cost effectiveness of nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy.
16. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

### **Appraisal of certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs**

#### **Part 1 – Open session**

17. The Vice-Chair welcomed invited experts, Mark Corbett and Laura Bojke, to the meeting and they introduced themselves to the committee.
18. The Vice-Chair welcomed company representatives from Novartis and UCB Pharma to the meeting.
19. The Vice-Chair asked all Committee members to declare any relevant interests
  - 19.1. Dr Aomesh Bhatt, Dr Andrew Black, Dr Ian Campbell, Dr Ian Davidson, Susan Dutton, Gillian Ells, Professor Paula Ghaneh, Sumithra Maheswaran, Professor Gary McVeigh, Professor David Meads, Professor Oluwafemi Oyebode, Malcolm Oswald, Dr Paula Parvulescu, Dr Mohit Sharma and Dr Lindsay Smith all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs.
  - 19.2. Professor Simon Dixon declared a non-personal non-specific financial interest as he is Director of a Health Economics Unit that has undertaken research for Novartis and comparator companies on unrelated topics. He was not directly involved in the work and the University of Sheffield received payment for the work.
    - 19.2.1 It was agreed that this declaration would not prevent Professor Simon Dixon from participating in this section of the meeting.
  - 19.3. Dr Susan Griffin declared a personal non-specific financial interest as she took part in an advisory board in 2015 and was personally reimbursed by Novartis. The topic of the advisory board related to non-small cell lung cancer.

- 19.3.1 It was agreed that this declaration would not prevent Dr Susan Griffin from participating in this section of the meeting.
- 19.4. Professor John Henderson declared a personal non-specific financial interest as he had received a speaker fee and incidental expenses from Novartis for an educational meeting on severe asthma in the last year.
- 19.4.1 It was agreed that this declaration would not prevent Professor John Henderson from participating in this section of the meeting.
20. The Vice-Chair asked all NICE Staff to declare any relevant interests.
- 20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs.
21. The Vice-Chair asked all other invited guests to declare their relevant interests.
- 21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs.
22. The Vice-Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
23. The Vice-Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
24. The Vice-Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
25. The Vice-Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

26. Discussion on confidential information continued.
27. The Committee continued to discuss the clinical and cost effectiveness of certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs.
- 27.1. The committee decision was based on consensus.

28. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD).

### **Appraisal of collagenase clostridium histolyticum for treating Dupuytren's contracture (post appeal)**

#### **Part 1 – Open session**

29. The Chair welcomed the invited experts, Henk Giele (who joined by telephone), Anna Schurer and Dr Paul Tappenden, to the meeting and they introduced themselves to the Committee.
30. The Chair welcomed company representatives from SOBI to the meeting.
31. The Chair asked all Committee members to declare any relevant interests
- 31.1. Dr Aomesh Bhatt, Dr Andrew Black, Dr Ian Campbell, Dr Ian Davidson, Professor Simon Dixon, Susan Dutton, Gillian Ells, Professor Paula Ghaneh, Dr Susan Griffin, Professor John Henderson, Sumithra Maheswaran, Professor Gary McVeigh, Professor David Meads, Professor Oluwafemi Oyeboode, Malcolm Oswald, Dr Paula Parvulescu, Dr Mohit Sharma and Dr Lindsay Smith all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of collagenase clostridium histolyticum for treating Dupuytren's contracture.
32. The Chair asked all NICE Staff to declare any relevant interests.
- 32.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of collagenase clostridium histolyticum for treating Dupuytren's contracture.
33. The Chair asked all other invited guests to declare their relevant interests.
- 33.1. Dr Paul Tappenden declared that he knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of collagenase clostridium histolyticum for treating Dupuytren's contracture.
- 33.2 Anna Schurer declared a specific non-personal financial interest as she is a trustee of a society which, this year, has received funding from Sobi.
- 33.2.1 It was agreed that this declaration would not prevent Anna Schurer from participating in this section of the meeting.

34. The Chair introduced the key issues arising from the Decision Support Unit report which had been commissioned to undertake further work to address the conclusions of the Appeal Panel.
35. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
36. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
37. The Chair then thanked the company representatives and experts for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

38. Discussion on confidential information continued.
39. The Committee continued to discuss the clinical and cost effectiveness of collagenase clostridium histolyticum for treating Dupuytren’s contracture.
  - 39.1. The committee decision was based on consensus.
40. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

## **Date, time and venue of the next meeting**

41. Tuesday 31 January 2017, from 10am – 5pm at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.